Literature DB >> 6653658

Long-term clorgyline treatment antagonizes the eating and motor function responses to m-chlorophenylpiperazine.

R M Cohen, C S Aulakh, D L Murphy.   

Abstract

Treatment for 21 days but not 3 days with clorgyline, a selective monoamine oxidase type A inhibitor with antidepressant effects, causes significant escape from m-chlorophenylpiperazine's effects on food intake, sedation level and induction of limb movements, but sensitizes rats to ejaculation. These findings support the prior reports of functional serotonin pathway adaptational changes in the motor system in response to antidepressant treatment and extend these findings to serotonin pathways involved in eating behavior.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6653658     DOI: 10.1016/0014-2999(83)90459-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers.

Authors:  D L Murphy; E A Mueller; J L Hill; T J Tolliver; F M Jacobsen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Chronic treatment with meta-chlorophenylpiperazine (m-CPP) alters behavioral and cerebral metabolic responses to the serotonin agonists m-CPP and quipazine but not 8-hydroxy-2(di-N-propylamino)tetralin.

Authors:  U Freo; H W Holloway; N H Greig; T T Soncrant
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Fenfluramine-induced suppression of food intake and locomotor activity is differentially altered by the selective type A monoamine oxidase inhibitor clorgyline.

Authors:  C S Aulakh; J L Hill; K M Wozniak; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

4.  Long-term imipramine treatment enhances locomotor and food intake suppressant effects of m-chlorophenylpiperazine in rats.

Authors:  C S Aulakh; R M Cohen; J L Hill; D L Murphy; J Zohar
Journal:  Br J Pharmacol       Date:  1987-08       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.